About macrogenics inc. - MGNX
MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.
MGNX At a Glance
MacroGenics, Inc.
9704 Medical Center Drive
Rockville, Maryland 20850-3368
| Phone | 1-301-251-5172 | Revenue | 149.50M | |
| Industry | Pharmaceuticals: Major | Net Income | -74,620,000.00 | |
| Sector | Health Technology | Employees | 293 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
MGNX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.68 |
| Price to Book Ratio | 1.834 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.282 |
| Enterprise Value to Sales | 0.124 |
| Total Debt to Enterprise Value | 5.762 |
MGNX Efficiency
| Revenue/Employee | 510,238.908 |
| Income Per Employee | -254,675.768 |
| Receivables Turnover | 11.179 |
| Total Asset Turnover | 0.559 |
MGNX Liquidity
| Current Ratio | 5.101 |
| Quick Ratio | 4.918 |
| Cash Ratio | 4.405 |
MGNX Profitability
| Gross Margin | 71.116 |
| Operating Margin | -48.723 |
| Pretax Margin | -50.363 |
| Net Margin | -49.913 |
| Return on Assets | -27.889 |
| Return on Equity | -86.945 |
| Return on Total Capital | -45.962 |
| Return on Invested Capital | -48.798 |
MGNX Capital Structure
| Total Debt to Total Equity | 192.049 |
| Total Debt to Total Capital | 65.759 |
| Total Debt to Total Assets | 40.354 |
| Long-Term Debt to Equity | 182.736 |
| Long-Term Debt to Total Capital | 62.57 |